Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Background Elderly patients with major depression have a poorer prognosis, are less
responsive to treatment, and show greater functional decline compared with younger …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

Ketamine is a phencyclidine derivative, which functions primarily as an antagonist of the N-
methyl-d-aspartate receptor. It has no affinity for gamma-aminobutyric acid receptors in the …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Study objective To evaluate the effectiveness and safety of S-ketamine for pain relief and
analgesic consumption in surgical patients. Design Systematic review and meta-analysis of …

Ketamine was introduced into clinical practice in the 1960s and continues to be both
clinically useful and scientifically fascinating. With considerably diverse molecular targets …

Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce
a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes …